Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.

  • Eli Lilly reported $86.5 billion revenue and $27.6 billion net income in 2026 fiscal year
  • Novo Nordisk had $49.0 billion revenue and $16.6 billion net income in 2026 fiscal year
  • Novo Nordisk is more affordable with lower valuation multiples than Eli Lilly

More from Tuesday 17 November →